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Association Between Clinical Risk Factors and Progression of
Chronic Kidney Disease in Children
Amy O. Staples,* Larry A. Greenbaum,† Jodi M. Smith,‡ Debbie S. Gipson,§ Guido Filler,储
Bradley A. Warady,¶ Karen Martz,** and Craig S. Wong*
*Department of Pediatrics, University of New Mexico, Albuquerque, New Mexico; †Department of Pediatrics, Emory
University, Atlanta, Georgia; ‡Department of Pediatrics, University of Washington, Seattle, Washington; §Department
of Pediatrics, University of Michigan, Ann Arbor, Michigan; 储Department of Pediatrics, University of Western Ontario,
London, Ontario, Canada; ¶Department of Pediatrics, Children’s Mercy Hospital, Kansas City, Missouri; and **Emmes
Corporation, Rockville, Maryland
Background and objectives: Children with chronic kidney disease (CKD) have an increased risk of progression to ESRD.
There is a need to identify treatments to slow the progression of CKD, yet there are limited data regarding clinical risk factors
that may be suitable targets to slow progression.
Design, setting, participants, & measurements: We performed a retrospective cohort study using the North American
Pediatric Renal Trials and Cooperative Studies CKD database. There were 4166 pediatric subjects with CKD stages II to IV.
Disease progression was defined as a GFR on follow-up of <15 ml/min per 1.73 m2 or termination in the registry because of
dialysis or transplantation. We used Kaplan-Meier and Cox proportional hazards methods to describe progression rates and
determine factors associated with CKD progression.
Results: In the univariate analysis, CKD progression was associated with age, gender, race, primary disease, CKD stage,
registration year, hematocrit, albumin, corrected calcium, corrected phosphorus, and use of certain medications. Factors that
remained significant in the multivariate analysis were age, primary disease, CKD stage, registration year, hypertension,
corrected phosphorus, corrected calcium, albumin, hematocrit, and medication proxies for anemia and short stature.
Conclusions: There are multiple risk factors associated with disease progression in the pediatric CKD population. Factors
that may be amenable to intervention include anemia, hypoalbuminemia, hyperphosphatemia, hypocalcemia, hypertension,
and short stature. Because of the retrospective nature of our study, confirmation of our results from ongoing prospective
studies is warranted before recommending prospective interventional trials.
Clin J Am Soc Nephrol 5: 2172–2179, 2010. doi: 10.2215/CJN.07851109

T

here is an urgent need to identify risk factors and
develop new methods to halt chronic kidney disease
(CKD) progression in children. Progression to ESRD at
a young age results in lifelong disability and significant reduction in lifespan. The expected remaining lifetime after ESRD in
the 0- to 14-year age group is 30 years (1). Among survivors of
childhood ESRD, health-related quality of life, rates of vocational placement, and independence from parents are lower
compared with peers in the general population (2,3). Although
the dominant causes of CKD in adults are diabetic nephropathy
and hypertension, nearly 60 to 70% of children affected with
CKD have congenital or inherited kidney disorders. Compared
with adults with CKD, pediatric patients with CKD require
greater amount of resources, specialized care, and care coordination to achieve optimal outcomes (4).
Significant research emphasis has been placed on early iden-
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tification of modifiable factors related to CKD progression.
Within the pediatric CKD population, hypertension and proteinuria have been shown to be strong clinical risk factors for
renal progression (5-10). Recently, Furth et al. (11) reported that
anemia and hypoalbuminemia were associated with an accelerated decline of GFR among 23 adolescents with CKD. Additionally, the recently published, prospective Effect of Strict
Blood Pressure Control and ACE-Inhibition on Progression of
Chronic Renal Failure in Pediatric Patients (ESCAPE) trial
found that optimal BP control can slow the progression of CKD
(10). The pediatric studies to date have been either limited in
range of clinical measures surveyed or sample size. Although
the literature is growing, these data within the pediatric CKD
population remain sparse, and the reported associations need
further validation.
Using the North American Renal Trials and Cooperative
Studies (NAPRTCS) Chronic Kidney Disease Registry, we report on multiple clinical factors associated with disease progression in a large pediatric cohort of patients with CKD.
Particular attention was paid to potentially modifiable factors
that may be targets for future clinical trials to slow CKD progression in children.
ISSN: 1555-9041/512–2172
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Materials and Methods

Factors Associated with CKD Progression

Table 1. Patient characteristics

Study Population
Details of the methods used for this analysis are published elsewhere
(12). Briefly, patients are eligible for enrollment in the voluntary
NAPRTCS database through their 20th birthday. Patients were classified by disease severity into one of five stages using the Kidney Disease
Outcomes Quality Initiative (KDOQI) CKD staging system (13). Estimated GFR (eGFR) was determined using the Schwartz equation (14).
The original Schwartz equation was used in this analysis because the
data analysis was complete before the publication of the revised equation. Disease progression was defined as an eGFR at any follow-up visit
of ⬍15 ml/min per 1.73 m2 or registry termination because of initiation
of dialysis or transplantation (cumulatively referred to as CKD stage V).
All patients with CKD stages II to IV at registry entry and any available
follow-up data were included in the analysis. Subjects excluded from
the study were those with a history of prior kidney transplant or
dialysis or those who were ⬍2 years of age, because the KDOQI staging
system is not applicable to children ⬍2 years old (13).

Statistical Analyses
Variables examined in the univariate analysis included age, gender,
race, primary diagnosis, CKD registry year (before 2000 and after),
erythropoietin use, growth hormone use, iron supplementation, hypertension (systolic or diastolic BP ⬎95 percentile for age, gender, and
height), anti-hypertensive medication use, parathyroid hormone (PTH),
CKD stage, anemia (hematocrit ⬍ 33%), height z-score, weight z-score,
body mass index z-score, corrected calcium (low, normal, high), ageadjusted phosphorus (normal, high), and albumin (as a dichotomous
variable ⱕ4 or ⬎4 g/dl). Serum calcium was adjusted for serum albumin as follows: measured Ca (mg/dl) ⫹ 0.8 ⫻ [4 ⫺ serum albumin
(g/dl)]. We defined a calcium value of 8.5 to 10.0 mg/dl as normal.
Calcium values ⬍8.5 mg/dl were classified as low, and values ⬎10.0
mg/dl as high. The definition of hyperphosphatemia was adjusted for
age in the following manner: ⱖ6.5 mg/dl for 2 to 5 years; ⱖ5.8 mg/dl
for 6 to 12 years; ⱖ4.5 mg/dl for 13 to 20 years.
Patients with any missing data were excluded from the multivariate
analysis (although included in the univariate analysis for the data that
were available). Additionally excluded from the multivariate analysis
were height, weight, and body mass index z-scores because they were
not significant in the univariate analysis. PTH was not included multivariate analysis because of ⬎1800 missing values. All other covariates
were included in the multivariate analysis.
Univariate analysis using Kaplan-Meier time-to-event curves and
log-rank tests were used to identify individual covariates associated
with disease progression. All significant factors were included in a
multivariate Cox proportional hazards regression model. Model selection used backward elimination methods, with final covariates significant at the 0.05 level. The analyses were performed using SAS version
8.2 (SAS Institute, Cary, NC).

Results
Population Demographics
A total of 6133 of the available patients enrolled in the
NAPRTCS CKD database had baseline eGFR and hematocrit
data available. Of those, 4166 were at least 2 years old, had one
set of follow-up data, and had CKD stages II to IV at registry
initiation. These patients were included in the initial analysis.
Demographic data for included patients is presented in Table 1.
At the time of registration, 79.8% were 6 years of age or older,
60.9% were white, 61.5% were male, and the most common
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N (%)
Total cases (ⱖ2 years)
Age (years)
2 to 5
6 to 12
⬎12
Gender
male
female
Race
white
African American
Hispanic
other
Primary diagnosis
obstructive uropathy
focal segmental glomerulosclerosis
renal dysplasia
reflux nephropathy
other
Anemia
hematocrit ⱖ33%
hematocrit ⬍33%
CKD stage
stage II
stage III
stage IV
CRI registry year
before 2000
2000 and after
Erythropoietin use
yes
no
Growth hormone use
yes
no
Calcium (corrected)
low
normal
high
Phosphorus
normal
elevated
Parathyroid hormone
⬍2⫻ upper limit
⬎2⫻ upper limit
unknown
Iron supplementation
yes
no
Anti-hypertensive medication use
yes
no
Albumin
ⱕ4.0 g/dl
⬎4.0 g/dl
Hypertension
yes
no

4166 (100)
836 (20.1)
1681 (40.4)
1649 (39.6)
2562 (61.5)
1604 (38.5)
2539 (60.9)
786 (18.9)
577 (13.9)
257 (6.2)
837 (20.1)
478 (11.5)
529 (12.7)
389 (9.3)
1833 (44.0)
2589 (62.1)
1577 (37.9)
828 (19.9)
2162 (51.9)
1176 (28.2)
2795 (67.1)
1371 (32.9)
557 (13.4)
3606 (86.6)
281 (6.7)
3878 (93.1)
214 (5.1)
2728 (65.5)
632 (15.2)
2654 (63.7)
1177 (28.3)
1477 (35.5)
853 (20.5)
1836 (44.1)
997 (23.9)
3157 (75.8)
1928 (46.3)
2230 (53.5)
1954 (46.9)
1674 (40.2)
1954 (46.9)
2154 (51.7)

Percents may not total 100% because of missing values.
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diagnosis was obstructive uropathy (20.1%). Although 37.9% of
patients were anemic (hematocrit ⬍ 33%), only 13.4% were
receiving erythropoietin and 23.9% supplemental iron. Additionally, 6.7% reported using growth hormone. Almost one half
(46.9%) of the patients were hypertensive, whereas 46.3% reported using anti-hypertensive medications. Regarding other
laboratory values at registration, 5.1% had a low serum calcium, 28.3% had elevated serum phosphorus, 20.5% had a PTH
value greater than two times the upper limit, and 46.9% had a
serum albumin ⱕ4.0 g/dl. The majority of patients had CKD
stage III at registry initiation (51.9%), followed by stage IV
(28.2%) and stage II (19.9%).
As described previously, the prevalence of anemia (hematocrit ⬍ 33%) was 21% in CKD stage II patients and increased to
59% in CKD stage IV patients (data not shown) (12).

Univariate Progression Rates

The median time to progression for all patients (n ⫽ 4166)
was 53.7 months from registry initiation. Table 2 provides the
Kaplan-Meier progression rates (the percent of patients who
progress to CKD stage V) at 1 and 3 years from the time of
registration, as well as the median months to reach CKD stage
V (number of months when 50% of the cases have progressed to
CKD stage V). African-American and Hispanic patients had a
higher rate of progression compared with white CKD patients
(median time to progression, 43.9 and 47.1 versus 60.3, respectively). Patients diagnosed with focal segmental glomerulosclerosis had a significantly shorter median time to progression
(22.9 months) than did those with obstructive uropathy (67.2
months), reflux nephropathy (88.5 months), renal dysplasia
(54.0 months), and other diagnoses (52.3 months).
Laboratory values collected at the time of registration
showed anemia, low serum calcium, high serum phosphorus,
and low serum albumin were associated with faster rate of
progression. Anemic patients progressed appreciably more
rapidly than did nonanemic patients (26.2 versus 77.3 months).
CKD patients with low serum-corrected calcium had a median
time to CKD stage V of 29.1 months compared with patients
with normal or high serum calcium (respectively, 52.7 and 55.6
months); those with high serum phosphorus levels had a median time to progression of 23.6 months compared with those
with normal serum phosphorus, who had a median time of 70.1
months. Hypoalbuminemic patients progressed more rapidly
compared with those with a normal serum albumin (respectively, 32.2 and 74.6 months).
Hypertensive patients progressed to CKD stage V almost 2
years sooner than did nonhypertensive patients (respectively,
43.8 and 63.7 months). Additionally, use of erythropoietin and
iron (likely indicating anemia) were associated with more rapid
progression to CKD stage V compared with nonuse of these
medications.
In the univariate analysis, all variables reported in Table 2
were significantly associated with progression to CKD stage V,
with severity of CKD and primary diagnosis showing the greatest association. The z-scores for height, weight, and body mass
index were not associated with renal progression.
Kaplan-Meier curves for disease progression associated with
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CKD stage and anemia are presented in Figures 1 and 2. At 5
years, 23.2% of those with CKD stage II at registry initiation
had progressed, whereas 86.4% of those with CKD stage IV at
initiation had reached stage V. Also, 71.0% of anemic patients
had progressed to stage V by 5 years, whereas only 41.6% of
nonanemic patients had progressed.

Multivariate Analysis for Renal Progression
To adjust for differences in CKD stage, primary diagnosis,
and other potential confounders, we performed a multivariate
proportional hazards regression analysis to evaluate independent risk factors for renal progression (Table 3). Results showed
younger age at time of registration was associated with a lower
risk of progression compared with older age (hazard ratio [HR],
0.72; 95% confidence interval [CI], 0.61 to 0.84). CKD stages III
and IV were associated with higher risk of disease progression
compared with stage II (HR, 2.0 and 6.68; 95% CI, 1.64 to 2.42
and 5.46 to 8.18, respectively). Using obstructive uropathy as
the referent group, focal segmental glomerulosclerosis was the
only diagnosis that was independently associated with a risk of
disease progression (HR, 1.77; 95% CI, 1.48 to 2.12).
Independent of the other factors, anemia, hypocalcemia, hyperphosphatemia, and hypoalbuminemia each remained significantly associated with a higher risk for renal progression. We
estimate that those with anemia at registration have an associated 52% increase in risk of disease progression compared with
the nonanemic patient (HR, 1.52; 95% CI, 1.36 to 1.69). Compared with patients with a normal serum calcium at time of
registration, those with hypocalcemia have a 29% higher risk
for renal progression independent of other factors (HR, 1.29;
95% CI, 1.06 to 1.58). Furthermore, those with hyperphosphatemia have a 41% increase in risk for renal progression
compared with those with normal serum phosphorus (HR, 1.41;
95% CI, 1.25 to 1.59). In the multivariate model, hypoalbuminemia was associated with a 67% higher risk for renal progression (HR, 1.67; 95% CI, 1.49 to 1.86).
Use of erythropoietin and use of growth hormone were considered surrogate indicators of anemia and short stature. The
surrogate indicators were associated with renal progression.
Anti-hypertensive medication use was not associated with renal progression when hypertensive status is included in the
multivariate model (Table 3).
To fully evaluate the relationships between the laboratory
measure of anemia and erythropoietin use, we evaluated two
interaction terms to identify any possible effect modification:
(1) erythropoietin use and anemia and (2) CKD stage and
anemia. Although we did find an increased risk of disease
progression for those with anemia not on erythropoietin
compared with those with anemia using erythropoietin (HR,
2.38 versus 1.60), when the term was added to the multivariate regression model, it became nonsignificant (P ⫽ 0.97;
data not shown). Assessment for interaction between anemia
and CKD stage with modeling of interactions terms was
similarly not significant in the multivariate setting (P ⫽ 0.11).
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Factors Associated with CKD Progression

Table 2. Time to progression: Kaplan-Meier rates
Patient Variables

1-Year Progression
Rate (%)

3-Year Progression
Rate (%)

Median Months
to Progression

All cases
Age (years)
2 to 5
6 to 12
⬎12
Gender
male
female
Race
white
African American
Hispanic
other
Primary diagnosis
obstructive uropathy
focal segmental glomerulosclerosis
renal dysplasia
reflux nephropathy
other
CKD stage
stage II
stage III
stage IV
Hypertension
yes
no
Laboratory values at registration
anemia
HCT ⱖ33%
HCT ⬍33%
calcium
low
normal
high
phosphorus
normal
high
albumin
ⱕ4.0 g/dl
⬎4.0 g/dl
Medication use at registration
anti-hypertensive medication use
yes
no
erythropoietin use
yes
no
iron supplementation
yes
no

17.3

39.4

53.7

11.8
16.0
21.6

28.6
38.4
46.9

78.6
52.8
40.9

16.5
18.6

37.9
42.0

57.5
48.0

16.3
19.5
17.3
21.0

37.5
44.1
41.2
41.5

60.3
43.9
47.1
51.8

10.8
31.7
14.3
10.5
18.2

29.4
61.7
39.3
28.4
39.7

67.2
22.9
54.0
88.5
52.3

3.5
8.6
43.0

15.4
28.8
74.5

137.7
67.8
15.5

21.0
14.2

44.8
34.5

43.8
63.7

10.3
29.0

28.2
57.6

77.3
26.2

33.5
16.9
17.1

53.3
39.3
40.3

29.1
52.7
55.6

10.9
32.3

29.8
62.5

70.1
23.6

24.5
10.4

52.2
27.6

32.2
74.6

21.5
13.7

45.7
34.1

42.7
64.0

40.9
13.7

68.8
34.8

17.7
61.2

29.2
13.5

56.3
34.0

28.8
63.7
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Table 3. Multivariate Cox regression analysis of factors
associated with CKD progression
Demographic Characteristics

Figure 1. Time to progression by CKD stage at registration.

Figure 2. Time to progression by anemia (defined by hematocrit
%) at registration.

Discussion
Although there has recently been significant emphasis on
factors associated with disease progression in adult CKD populations, little is known about the pediatric population. Our
review of a large pediatric CKD cohort identified a number of
clinical factors associated with renal progression, several of
which are potentially modifiable and provide potential targets
for interventional trials aimed at slowing CKD progression. The
Kaplan-Meier– based estimates regarding time to progression
(Table 2) provide benchmark progression rates for future studies and are potentially useful to provide anticipatory guidance
for families affected by childhood CKD. In our multivariate
analysis, we found that age at registration, CKD stage at registration, cause of CKD, hypertension, anemia, hypoalbuminemia, hyperphosphatemia, hypocalcemia, and reported medications used to treat anemia and short stature were associated with
CKD progression in children.
In adults with CKD, Hunsicker et al. (15) identified that renal
progression was associated with race, degree of proteinuria,
mean arterial pressure, HDL, and underlying diagnosis using
data from the Modification of Diet in Renal Disease Study in
1997. Only mean arterial pressure, HDL cholesterol levels, and
possibly degree of proteinuria were associated factors found in

Age (years)
2 to 5
6 to 12
⬎12
CKD stage
stage II
stage III
stage IV
Primary diagnosis
dysplasia
reflux nephropathy
focal segmental
glomerulosclerosis
other
obstructive uropathy
Cohort year
1994 to 1999
2000 to 2008
Hypertension
yes
no
Laboratory data at registration
anemia
hematocrit ⬍33%
hematocrit ⬎33%
calcium
⬍8.5 mg/dl
ⱖ8.5 mg/dl
phosphorus (high)
high
normal
albumin
ⱕ4.0 g/dl
⬎4.0 g/dl
Medication use at registration
erythropoietin use
yes
no
growth hormone use
yes
no

Hazard
Ratio

95%
Confidence
Interval

0.72
0.97
1.00

0.61 to 0.84a
0.85 to 1.10
—

1.00
2.00
6.68

—
1.64 to 2.42a
5.46 to 8.18a

1.15
0.85
1.77

0.96 to 1.37
0.68 to 1.06
1.48 to 2.12a

1.13
1.00

0.98 to 1.30
—

0.78
1.00

0.69 to 0.88a
—

1.26
1.00

1.14 to 1.40a
—

1.52
1.00

1.36 to 1.69a
—

1.29
1.00

1.06 to 1.58b
—

1.41
1.00

1.25 to 1.59a
—

1.67
1.00

1.49 to 1.86a
—

1.30
1.00

1.14 to 1.49c
—

1.24
1.00

1.04 to 1.48b
—

Factors in the multivariate analysis include age, gender,
race, hematocrit, albumin, CKD stage, primary diagnosis,
cohort year, calcium, phosphorus, anemia, hypertension, iron
supplementation, growth hormone use, and erythropoietin
use.
a
P ⬍ 0.0001.
b
P ⬍ 0.05.
c
P ⬍ 0.005.
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the study of Hunsicker et al. that might be amenable to correction. Similarly, Jungers et al. (16) identified primary disease and
degree of proteinuria as major determinates of renal progression in their adult population of CKD patients without diabetic
kidney disease. Although these associated factors may be helpful in predicting the rate of CKD progression for patients, only
modifiable factors have the potential of slowing the rate of
progression.
Our finding of increased risk of disease progression in patients with hypertension (HR, 1.26) supports the findings of
prior studies using the NAPRTCS data. Mitsnefes et al. (6) used
the NAPRTCS database to evaluate the association of hypertension and disease progression. In their evaluation of 3834
patients with CKD, they found that systolic hypertension was a
significant independent risk factor for disease progression with
a relative risk of 1.2. Recently additional prospective data from
the ESCAPE trial has confirmed that optimal BP control can
significantly retard the progression of CKD (10). The ESCAPE
study provided firm evidence that higher BP and furthermore
high levels of proteinuria increases the rate of renal progression
in children. The NAPRTCS database does not collect data on
proteinuria, and hence this was not evaluated in our analysis.
Our study confirmed findings of two other recent pediatric
studies focused on associated risk factors for renal progression.
Soares et al. (9) performed a retrospective review of 107 pediatric patients aimed to identify predictive factors associated
with CKD progression. Our study confirmed their findings that
primary cause of CKD and initial CKD stage were associated
with renal progression in children. Although the findings from
Soares et al. are valuable to the literature, their study was
limited in sample size and lacked variables for modifiable risk
factors, such as those identified in our study. Similar to what
has been reported by Furth et al. (11), we found that anemia and
hypoalbuminemia were associated with pediatric CKD progression. Although the study by Furth et al. was a multicenter
prospective study, it was limited in size (only to 23 subjects)
and was limited to adolescents and is thus not generalizable to
younger CKD patients. Although our study was retrospective,
our data included ⬎4000 pediatric patients, with 60% of our
population being 12 years of age or younger. Furthermore,
Furth et al. (11) defined anemia as a hematocrit ⬍36%. Although this may be one definition of anemia, the KDOQI anemia guidelines specify a hematocrit of ⬍33% as the cut-off for
anemia (17), which was the defined anemia threshold for our
study.
In addition to anemia and hypoalbuminemia, we also identified that hypocalcemia and hyperphosphatemia were independent risk factors for renal progression in these children with
CKD. Voormolen et al. (18) have previously found an association between hyperphosphatemia and a more rapid decline in
renal function (as well as mortality) in the predialysis CKD
population. However, their study included only adults with an
eGFR ⬍20 ml/min per 1.73 m2.
The use of medication in this cohort identified patients who
were at risk for renal progression. It is notable that we found an
increased rate of progression in patients using erythropoietin
compared with those not using erythropoietin (HR, 1.29; 95%

Factors Associated with CKD Progression
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CI, 1.13 to 1.48). This association is likely not caused by the use
of erythropoietin itself but rather that this variable served as a
surrogate marker for the condition of anemia that is not fully
explained by hematocrit alone. Because a very small proportion
of patients with anemia are being treated with erythropoietin in
our cohort (13%), it may be that those with more significant
anemia (possible correlating with more significant disease) are
those treated with erythropoietin, leading to the association of
erythropoietin use and disease progression. Although subjects
with anemia had an associated faster rate of progression, we
could not detect a difference in the rate of progression with
those treated with erythropoietin, when we modeled the relationship with an interaction term. Additionally, we did see that
those with anemia who were not treated with erythropoietin
had an increased risk of disease progression in the univariate
analysis, suggesting that it is the anemia and not the use of
erythropoietin that contributes to disease progression.
Furthermore, growth hormone as a surrogate measure for
short stature was associated with a higher risk for renal progression independent of other factors in the analysis. Short
stature in the pediatric CKD population is associated with a
lower quality of life, increased rate of hospitalization, and
death. Although the reported association between the use of
growth hormone and renal progression is intriguing, a further
analysis of the association with height was beyond the scope of
our analysis but deserves further study.
We feel it important to acknowledge the limitations of our
study. First, the NAPRTCS database, while being the largest
database of its kind, is a voluntary registry. Thus, there may be
a significant number of pediatric CKD patients who are not
enrolled. Additionally, there is known to be a significant
amount of missing data, which led to the exclusion of numerous patients in the multivariate analysis. Moreover, the available data are limited to information that is routinely collected in
the database at 6-months intervals, not allowing for more complete or detailed information. Most importantly, it did not
allow for the assessment of an association between chronic
inflammatory state or degree of proteinuria and risk of disease
progression, both areas of significant interest of late (19).
In these data, there is evidence of survivorship bias with
evidence of a small but significant difference in progression
rates between cohort years. Those with less severe disease and
therefore slower progression may remain in the CKD cohort for
longer and contribute more time at risk, leading the older
cohort of patients to seem to have a lower risk of progression.
Adjusting the analysis for cohort year will address this bias.
However, as with any observational study, there exists the
possibility of other sources of unmeasured bias that we were
not able to address.
The eGFRs (and therefore CKD stages) were calculated using
the original Schwartz equation (14). Our data analysis predated
the revision of the recently published pediatric GFR estimating
equation (20). The revised estimating equation for GFR was
used for serum creatinine concentrations by enzymatic methods, whereas the original Schwartz formula is appropriate for
serum creatinine concentrations performed by the Jaffe method
(21). We acknowledge that having no indication of type of
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creatinine assay is a limitation of the database. We applied the
original Schwartz formula to estimate GFRs for this analysis
because of concern that applying the updated estimating equation would tend to exaggerate the rate of progression and
overestimate the strength of association, especially for those in
earlier cohort years when the Jaffe method for creatinine determination was more commonly used.
It is important to emphasize that this study showed only
association between identifiable risk factors and disease progression and did not show evidence of cause and effect. Although we controlled for many potentially confounding variables, it is possible that identified risk factors may be acting as
surrogate markers for other conditions that were not collected
as part of the NAPRTCS database. The ongoing prospective
cohort study of CKD in children (22) addresses many of the
limitations of this study and will provide an appropriate platform
to replicate the findings from our retrospective cohort study.
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3.

4.

5.

6.

Conclusions

Our retrospective cohort study of ⬎4000 pediatric patients
with CKD identified multiple risk factors associated with CKD
progression. Our findings underline the importance of early
detection and management of pediatric CKD in an attempt to
delay CKD progression. Although not modifiable, the CKD risk
factors of primary cause of CKD, CKD stage, and age allow
identification of high-risk groups for intensive monitoring and
attentive management. We were able to identify several clinical
risk factors associated with renal progression in children, including anemia, hyperphosphatemia, hypocalcemia, hypertension, and short stature. These may represent potential targets
for improved management of pediatric CKD patients that have
the potential to impact the rates of disease progression. Given
the limitations of our study design, our findings need to be
confirmed by ongoing prospective studies of pediatric CKD
before recommending definitive guidelines or interventions.
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